Free Access
Med Sci (Paris)
Volume 24, Number 12, Décembre 2008
Page(s) 1012 - 1014
Section Nouvelles
Published online 15 December 2008
  1. Buchou T, Cochet C. La protéine kinase CK2, une enzyme qui cultive la différence Med Sci (Paris) 2003; 19 : 709–16. [Google Scholar]
  2. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369 : 1–15. [Google Scholar]
  3. Ayoub N, Jeyasekharan AD, Bernal JA, Venkitaraman AR. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008; 453 : 682–6. [Google Scholar]
  4. Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007; 43 : 928–34. [Google Scholar]
  5. O-Charoenrat P, Rusch V, Talbot SG, et al. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 2004; 10 : 5792–803. [Google Scholar]
  6. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13 : 1019–28. [Google Scholar]
  7. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2004; 2 : 712–21. [Google Scholar]
  8. Pagano MA, Cesaro L, Meggio F, Pinna, LA. Protein kinase CK2: a newcomer in the druggable kinome. Biochem Soc Trans 2006; 34 : 1303–6. [Google Scholar]
  9. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008; 1784 : 33–47. [Google Scholar]
  10. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007; 12 : 622–633. [Google Scholar]
  11. Prudent R, Moucadel V, Laudet B, et al. Identification of Polyoxometalates as nanomolar noncompetitive inhibitors of Protein Kinase CK2. Chemistry Biology 2008; 15 : 683–92. [Google Scholar]
  12. Prudent R, Moucadel V, López-Ramos M, et al. Expanding the chemical diversity of CK2 inhibitors. Mol Cell Biochem 2008; 316 : 71–85. [Google Scholar]
  13. Laudet B, Barette C, Dulery V, et al. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem J 2007; 408 : 363–73. [Google Scholar]
  14. Laudet B, Prudent R, Filhol O, Cochet C. Des agents thérapeutiques ciblant des interactions protéine-protéine : mythe ou réalité ? Med Sci (Paris) 2007; 23 : 273–8. [Google Scholar]
  15. Hasenknopf B. Polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front Biosci 2005; 10 : 275–87. [Google Scholar]
  16. Yamase T. Anti-tumor, -viral, and -bacterial activities of polyoxometalates for realizing an inorganic drug. J Mater Chem 2005; 15 : 4773–82. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.